Key Insights

Highlights

Treatment Research

1 treatments under study, led by 68gaa3

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Early P 1 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06194630Early Phase 1Unknown

Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer

Showing all 1 trials

Research Network

Common Treatments

  • 68gaa31

Active Sponsors

  • Peking Union Medical College Hospital1

Related Conditions

  • Lung Cancer1

Activity Timeline